NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Forecast, Price & News

$0.80

0.00 (-0.29%)

(As of 04:00 PM ET)

Compare

Today's Range: $0.80
▼
$0.85
50-Day Range: $0.72
▼
$0.95
52-Week Range: $0.63
▼
$1.40

Volume: 46,761 shs
Average Volume: 99,731 shs
Market Capitalization: $83.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

vTv Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 398.8% Upside
$4.00 Price Target
Short Interest: Bearish
4.23% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.32
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

898th out of 986 stocks

Pharmaceutical Preparations Industry

438th out of 479 stocks

3.5

Analyst's Opinion

Consensus Rating
vTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, vTv Therapeutics has a forecasted upside of 398.8% from its current price of $0.80.
Amount of Analyst Coverage
vTv Therapeutics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.23% of the float of vTv Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
vTv Therapeutics has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
Change versus previous month
Short interest in vTv Therapeutics has recently decreased by 1.69%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
vTv Therapeutics does not currently pay a dividend.
Dividend Growth
vTv Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VTVT.

0.9

News and Social Media Coverage

News Sentiment
vTv Therapeutics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for vTv Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for VTVT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.80% of the stock of vTv Therapeutics is held by insiders.
Percentage Held by Institutions
Only 8.50% of the stock of vTv Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of vTv Therapeutics is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of vTv Therapeutics is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About vTv Therapeutics (NASDAQ:VTVT) Stock

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Stock News Headlines

June 6, 2023 | bizjournals.com

As it advances its Type 1 Diabetes treatment, vTv Therapeutics increases cash position, decreases net loss in Q1

June 6, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on vTv Therapeutics (NASDAQ:VTVT)

June 9, 2023 | Vector Vest (Ad)

Master Market Movements: Free Stock Analysis Report with Predictive Buy/Sell/Hold Insights!

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 28, 2023 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Receives New Coverage from Analysts at StockNews.com

May 24, 2023 | finance.yahoo.com

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 21, 2023 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

May 17, 2023 | americanbankingnews.com

Brokers Offer Predictions for vTv Therapeutics Inc.'s FY2023 Earnings (NASDAQ:VTVT)

May 12, 2023 | finanznachrichten.de

vTv Therapeutics Inc.: vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

June 9, 2023 | Vector Vest (Ad)

Master Market Movements: Free Stock Analysis Report with Predictive Buy/Sell/Hold Insights!

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 12, 2023 | finance.yahoo.com

vTv Therapeutics Insider Ups Holding During Year

May 12, 2023 | finance.yahoo.com

vTv Therapeutics Insider Ups Holding During Year \

May 12, 2023 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Earns Hold Rating from Analysts at StockNews.com

May 11, 2023 | finance.yahoo.com

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 4, 2023 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at StockNews.com

April 28, 2023 | morningstar.com

vTv Therapeutics Inc Class A

April 26, 2023 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at StockNews.com

April 20, 2023 | finance.yahoo.com

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

April 18, 2023 | msn.com

Promising Upsides on these Biotech Penny Stocks

April 11, 2023 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com

March 25, 2023 | finance.yahoo.com

3 Pharma Stocks That Could Benefit from Global Healthcare Trends

March 6, 2023 | finance.yahoo.com

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 6, 2023 | finance.yahoo.com

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

March 3, 2023 | finance.yahoo.com

vTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 88% if they invested five years ago

February 27, 2023 | finance.yahoo.com

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

February 1, 2023 | finance.yahoo.com

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

January 31, 2023 | reuters.com

VTVT.PH - | Stock Price & Latest News | Reuters

January 20, 2023 | finance.yahoo.com

Private equity firms in vTv Therapeutics Inc. (NASDAQ:VTVT) are its biggest bettors, and their bets paid off as stock gained 21% last week

See More Headlines

VTVT Price History

30 days | 90 days | 365 days | Advanced Chart

VTVT Company Calendar

Last Earnings: 5/11/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VTVT
CUSIP: N/A
CIK: 1641489
Web: www.vtvtherapeutics.com
Phone: (336) 841-0300
Fax: 336-841-0310
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +393.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,160,000.00
Net Margins: N/A
Pretax Margin: -119,016.66%
Return on Equity: N/A
Return on Assets: -49.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.42
Quick Ratio: 2.42

Sales & Book Value

Annual Sales: $2.02 million
Price / Sales: 41.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.10) per share
Price / Book: -8.10

Miscellaneous

Outstanding Shares: 104,580,000
Free Float: 103,740,000
Market Cap: $84.71 million
Optionable: Not Optionable
Beta: -1.20

Key Executives

Paul Jai Sekhri
President, Chief Executive Officer & Director

Steven Tuch
Chief Financial Officer

Carmen Valcarce
Chief Scientific Officer & Executive VP

Elizabeth M. Keiley
Executive Vice President & General Counsel

Vanessa McDade
Chief Administration Officer

Key Competitors

View All Competitors

Insiders

John A Fry
Bought 20,539 shares on 11/28/2022
Total: $17,047.37 ($0.83/share)

View All Insider Transactions

VTVT Stock - Frequently Asked Questions

Should I buy or sell vTv Therapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTVT shares.
View VTVT analyst ratings or view top-rated stocks.
What is vTv Therapeutics' stock price forecast for 2023?: 2 brokerages have issued 1-year target prices for vTv Therapeutics' stock. Their VTVT share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 393.8% from the stock's current price.
View analysts price targets for VTVT or view top-rated stocks among Wall Street analysts.
How have VTVT shares performed in 2023?: vTv Therapeutics' stock was trading at $0.6628 at the start of the year. Since then, VTVT shares have increased by 22.2% and is now trading at $0.81.
View the best growth stocks for 2023 here.
When is vTv Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VTVT earnings forecast.
How were vTv Therapeutics' earnings last quarter?: vTv Therapeutics Inc. (NASDAQ:VTVT) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02.
What other stocks do shareholders of vTv Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?: (VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
What is vTv Therapeutics' stock symbol?: vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How do I buy shares of vTv Therapeutics?: Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is vTv Therapeutics' stock price today?: One share of VTVT stock can currently be purchased for approximately $0.81.
How much money does vTv Therapeutics make?: vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $84.71 million and generates $2.02 million in revenue each year. The biotechnology company earns $-19,160,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.
How can I contact vTv Therapeutics?: vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310.

This page (NASDAQ:VTVT) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial